PACTR202204794105273

Safety and tolerability of combining deworming and anti-malaria drugs among pre-school and school-aged children in Senegal

Feasibility and effectiveness of delivering mass drug administration for helminths through the seasonal malaria chemoprevention (SMC) platform in a West African paediatric population
London School of Hygiene Tropical Medicine·Not Applicable·Pan Africa Clinical Trials Registry·drugNot yet recruiting
Study focus
Intervention type
drug
Sponsor & location
Primary sponsor
London School of Hygiene Tropical Medicine
Funder
UK Research and Innovation
Location
Senegal
Timeline & enrollment
Phase
Not Applicable
Start date
Jan 01, 1900
End date
Jan 01, 1900
Summary

Malaria remains a major health problem, especially in sub-Saharan Africa where more than 90% of the disease and deaths occur in children. Adding to this high burden among the children is the co-existence of intestinal and genito-urinary worms. Prominent among these are soil-transmitted helminths and Schistosomiasis. Existing control programmes for the worms are operating below the expected level, despite the commitments and support that followed the 2012 London Declaration of achieving 75% treatment coverage by 2020. On the other hand, a malaria prevention programme, called Seasonal Malaria Chemoprevention (SMC), introduced in the same year 2012 has achieved more than 75% treatment coverage and prevented 75-85% cases of uncomplicated and severe malaria in children. This encouraging development supports the need to explore the strategies involving the integration of worm control with successful platforms such as SMC. This would align worm and malaria control with the WHO road map for Neglected Tropical Diseases (NTD) of ending the neglect to attain Sustainable Development Goals by eradicating diseases of poverty and promoting health and well-being for those at risk.Given this context, it is important to develop a treatment approach that combines malaria and helminth control in an integrated framework that will be safe, effective and easy to deliver. This study will, therefore, investigate the feasibility and effectiveness of co-administration of anthelminthic and SMC drugs in a high-risk paediatric population living in a malaria-helminth co-endemic setting in Senegal, West Africa. This study is designed to test the hypothesis that co-administration of SMC and anthelminthic drugs will be safe and tolerated among children aged 1-14 years and that the incidence of side effects will not be significant. The objectives of this study are to assess the safety, tolerability, and effects of co-administration of SMC and anthelminthic drugs among the children.

ICD-10 classifications
Certain infectious and parasitic diseasesInfestation, unspecifiedOther specified infestationsOther infestationsSequelae of infectious and parasitic diseases
Data source
Registry
Pan Africa Clinical Trials Registry
Trial ID
PACTR202204794105273
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for PACTR202204794105273 through Pure Global AI's free database. This Not Applicable trial is sponsored by London School of Hygiene Tropical Medicine and is currently Not yet recruiting. The study focuses on Infections and Infestations; Infections and Infestations.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.